Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Atea Pharmaceuticals Inc
(NQ:
AVIR
)
3.960
+0.130 (+3.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atea Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
April 29, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
March 27, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Recap: Atea Pharmaceuticals Q4 Earnings
February 28, 2024
Via
Benzinga
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Earnings Preview
February 27, 2024
Via
Benzinga
Atea Pharmaceuticals's Earnings Outlook
November 07, 2023
Via
Benzinga
Earnings Preview For Atea Pharmaceuticals
August 07, 2023
Via
Benzinga
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
February 21, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
January 09, 2024
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for
Via
Benzinga
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
January 08, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 13, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 02, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
November 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
June 15, 2023
Combination Offers Opportunity to Improve Standard of Care with Potential for Short Duration, Protease Inhibitor-Free Treatment
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 05, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
May 30, 2023
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 30, 2023
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 30, 2023
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
Via
Benzinga
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 23, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
May 22, 2023
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 22, 2023
Via
Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 22, 2023
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.